文献速递乳腺癌

乳腺癌从原位癌向浸润性癌转变过程中的免疫逃逸

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.
PubMed 文献 · Cancer Discov · 2017-06-26

该研究分析了正常乳腺组织、导管原位癌(DCIS)和浸润性导管癌(IDC)中白细胞的组成,发现组织与肿瘤亚型特异的免疫细胞差异,IDC中CD8+特征下降、活化GZMB+CD8+ T细胞减少、T细胞受体克隆多样性降低,而TIGIT+ T细胞在DCIS更常见,PD-L1高表达和CD274扩增仅见于三阴性IDC,17q12趋化因子簇与ERBB2共扩增将HER2+肿瘤分为免疫和临床 distinct 亚型,表明肿瘤进展过程中癌细胞与免疫微环境共同演化。

要点

  • IDC较DCIS活化GZMB+CD8+ T细胞减少,T细胞受体克隆多样性显著降低。
  • TIGIT+ T细胞在DCIS更常见,PD-L1高表达和CD274扩增仅见于三阴性IDC。
  • 17q12趋化因子簇与ERBB2共扩增将HER2+乳腺肿瘤分为免疫和临床 distinct 亚型。

核心结论

  • 乳腺癌从原位癌向浸润性癌转变过程中,肿瘤免疫环境向活性降低的方向切换,并鉴定出塑造肿瘤演化的免疫调节因子和基因组改变。

研究设计与样本

  • 研究分析了正常乳腺组织、导管原位癌(DCIS)和浸润性导管癌(IDC)中白细胞的组成,并对CD45+CD3+ T细胞进行基因表达谱分析。

主要发现

  • 多种细胞类型(包括T细胞和中性粒细胞)存在显著的组织和肿瘤亚型特异性差异。
  • CD45+CD3+ T细胞的基因表达谱显示IDC中CD8+特征下降。
  • 免疫荧光分析显示IDC中活化GZMB+CD8+ T细胞少于DCIS,包括配对的DCIS和复发性IDC。
  • DCIS中T细胞受体克隆多样性显著高于IDC。
  • 表达免疫检查点蛋白TIGIT的T细胞在DCIS中更常见,而PD-L1高表达和CD274(编码PD-L1)扩增仅在三阴性IDC中检测到。

关键数值与推荐

  • 17q12趋化因子簇与ERBB2共扩增将HER2+乳腺肿瘤分为免疫学和临床上不同的亚型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To investigate immune escape during breast tumor progression, we analyzed the composition of leukocytes in normal breast tissues, ductal carcinoma in situ (DCIS), and invasive ductal carcinomas (IDC). We found significant tissue and tumor subtype-specific differences in multiple cell types including T cells and neutrophils. Gene expression profiling of CD45+CD3+ T cells demonstrated a decrease in CD8+ signatures in IDCs. Immunofluorescence analysis showed fewer activated GZMB+CD8+ T cells in IDC than in DCIS, including in matched DCIS and recurrent IDC. T-cell receptor clonotype diversity was significantly higher in DCIS than in IDCs. Immune checkpoint protein TIGIT-expressing T cells were more frequent in DCIS, whereas high PD-L1 expression and amplification of CD274 (encoding PD-L1) was only detected in triple-negative IDCs. Coamplification of a 17q12 chemokine cluster with ERBB2 subdivided HER2+ breast tumors into immunologically and clinically distinct subtypes. Our results show coevolution of cancer cells and the immune microenvironment during tumor progression.Significance: The design of effective cancer immunotherapies requires the understanding of mechanisms underlying immune escape during tumor progression. Here we demonstrate a switch to a less active tumor immune environment during the in situ to invasive breast carcinoma transition, and identify immune regulators and genomic alterations that shape tumor evolution. Cancer Discov; 7(10); 1098-115. ©2017 AACR.See related commentary by Speiser and Verdeil, p. 1062This article is highlighted in the In This Issue feature, p. 1047.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. Cancer Discov. 2017. PMID: 28652380. doi:10.1158/2159-8290.CD-17-0222

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。